- Home
- LVTX
as 07-26-2024 4:00pm EST
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
| Founded: | 2016 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 47.3M | IPO Year: | 2021 |
| Target Price: | $6.00 | AVG Volume (30 days): | 91.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.13 - $6.47 | Next Earning Date: | 08-20-2024 |
| Revenue: | $13,627,174 | Revenue Growth: | -36.01% |
| Revenue Growth (this year): | 5.36% | Revenue Growth (next year): | N/A |
Latest LAVA Therapeutics N.V. News
LVTX Breaking Stock News: Dive into LVTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
GlobeNewswire
2 months ago
LAVA Announces Annual Meeting of Shareholders
GlobeNewswire
2 months ago
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
2 months ago
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
GlobeNewswire
3 months ago
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
Simply Wall St.
4 months ago
LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint
GlobeNewswire
4 months ago
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
GlobeNewswire
5 months ago
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
Compare LVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LVTX LAVA Therapeutics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.